Stroke prevention in atrial fibrillation: findings from Tuscan FADOI Stroke Registry

  • Luca Masotti | luca.masotti@tin.it UO Medicina Interna, Ospedale di Cecina (LI), Italy.
  • Rinaldo Innocenti UO Medicina Interna, Ospedale Careggi, Firenze, Italy.
  • Stefano Spolveri UO Medicina Interna, Ospedale Borgo San Lorenzo, Firenze, Italy.
  • Irene Chiti UO Medicina Interna, Ospedale di Pescia (PT), Italy.
  • Grazia Panigada UO Medicina Interna, Ospedale di Pescia (PT), Italy.
  • Cristiana Seravalle UO Medicina Interna, Ospedale Santa Maria Nuova, Firenze, Italy.
  • Giancarlo Landini UO Medicina Interna, Ospedale Santa Maria Nuova, Firenze, Italy.
  • Alberto Fortini UO Medicina Interna, Ospedale San Giovanni di Dio, Firenze, Italy.
  • Rino Migliacci UO Medicina Interna, Ospedale di Cortona (AR), Italy.
  • Raffaele Laureano UO Medicina Interna, Ospedale Santa Maria Annunziata, Firenze, Italy.
  • for Tuscan FADOI Stroke Registry Investigators

Abstract

Despite vitamin K antagonists (VKAs) are considered the first choice treatment for stroke prevention in atrial fibrillation (AF), literature shows their underuse in this context. Since data about VKAs use prior and after acute stroke lack, the aim of this study was to focus on management of anticoagulation with VKAs in this context. Data were retrieved from Tuscan FADOI Stroke Registry, an online data bank aimed to report on characteristics of stroke patients consecutively admitted in Internal Medicine wards in 2010 and 2011. In this period 819 patients with mean age 76.5±12.3 years were enrolled. Data on etiology were available for 715 of them (88.1%), 87% being ischemic and 13% hemorrhagic strokes. AF was present in 238 patients (33%), 165 (69.3%) having a known AF before hospitalization, whereas 73 patients (31.7%) received a new diagnosis of AF. A percentage of 89% of strokes in patients with known AF were ischemic and 11% hemorrhagic. A percentage of 86.7% of patients with known AF had a CHADS2 ≥2, but only 28.3% were on VKAs before hospitalization. A percentage of 78.8% of patients treated with VKAs before stroke had an international normalized ratio (INR) ≤2.0; 68.7% of patients with VKAs-related hemorrhagic strokes had INR ≤3.0. Combined endpoint mortality or severe disability in patients with ischemic stroke associated with AF was present in 47%, while it was present in 19.30% and 19.20% of atherothrombotic and lacunar strokes, respectively. At hospital discharge, VKAs were prescribed in 25.9% of AF related ischemic stroke patients. AF related strokes are burdened by severe outcome but VKAs are dramatically underused in patients with AF, even in higher risk patients. Efforts to improve anticoagulation in this stroke subtype are warranted.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-06-12
Info
Issue
Section
Original Articles
Keywords:
Atrial fibrillation, stroke, vitamin K antagonists, oral anticoagulant therapy, outcome, prevention.
Statistics
  • Abstract views: 1217

  • PDF: 1028
  • Appendix: 494
  • HTML: 619
How to Cite
Masotti, L., Innocenti, R., Spolveri, S., Chiti, I., Panigada, G., Seravalle, C., Landini, G., Fortini, A., Migliacci, R., Laureano, R., & Investigators, for T. F. S. R. (2014). Stroke prevention in atrial fibrillation: findings from Tuscan FADOI Stroke Registry. Italian Journal of Medicine, 9(2), 134-140. https://doi.org/10.4081/itjm.2014.450